115 related articles for article (PubMed ID: 12188025)
1. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma.
Dueñas-Gonzalez A; Verastegui E; Lopez-Graniel C; Gonzalez A; Mota A; Barrera-Franco JL; Meneses A; Chanona J; de la Garza J; Chavez-Blanco A; Hadden JW
Int Immunopharmacol; 2002 Jun; 2(7):1007-16. PubMed ID: 12188025
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.
Wolf GT; Liu S; Bellile E; Sartor M; Rozek L; Thomas D; Nguyen A; Zarins K; McHugh JB;
Oral Oncol; 2020 Dec; 111():104928. PubMed ID: 32738599
[TBL] [Abstract][Full Text] [Related]
5. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
Meneses A; Verastegui E; Barrera JL; Zinser J; de la Garza J; Hadden JW
Arch Pathol Lab Med; 1998 May; 122(5):447-54. PubMed ID: 9593347
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemotherapy for advanced cervical cancer].
Kodama J; Ikuhashi H; Hongo A; Mizutani Y; Miyagi Y; Yoshinouchi M; Kobashi Y; Okuda H; Kudo T
Gan To Kagaku Ryoho; 1999 Jan; 26(1):89-92. PubMed ID: 9987503
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.
Liu S; Bellile E; Nguyen A; Zarins K; D'Silva N; Rozek L; Wolf GT; Sartor MA;
Oral Oncol; 2021 Dec; 123():105587. PubMed ID: 34717154
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience.
Selvaggi L; Loizzi V; DI Gilio AR; Nardelli C; Cantatore C; Cormio G
Int J Gynecol Cancer; 2006; 16(2):631-7. PubMed ID: 16681738
[TBL] [Abstract][Full Text] [Related]
9. Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.
Zannoni GF; Vellone VG; Carbone A
Int J Gynecol Pathol; 2008 Apr; 27(2):274-81. PubMed ID: 18317212
[TBL] [Abstract][Full Text] [Related]
10. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
[TBL] [Abstract][Full Text] [Related]
11. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
dos Reis R; Frumovitz M; Milam MR; Capp E; Sun CC; Coleman RL; Ramirez PT
Gynecol Oncol; 2007 Dec; 107(3):458-63. PubMed ID: 17854872
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix.
Iwasaka T; Fukuda K; Hara K; Yokoyama M; Nakao Y; Uchiyama M; Sugimori H
Gynecol Oncol; 1998 Aug; 70(2):236-40. PubMed ID: 9740697
[TBL] [Abstract][Full Text] [Related]
13. [Histological evaluation of cervical carcinomas in FIGO stage Ib2/IIa after neoadjuvant chemotherapy].
CHEN XD; SHI HY; LÜ WG; QIN JL
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):173-6. PubMed ID: 21575388
[TBL] [Abstract][Full Text] [Related]
14. Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma: II. Its impact on clinical response and subsequent surgery.
Motoyama S; Takeuchi S; Hamana S; Ku Y; Miyahara Y; Tateiwa Y; Yoshida S; Maruo T
Am J Clin Oncol; 2001 Jun; 24(3):247-50. PubMed ID: 11404494
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
[TBL] [Abstract][Full Text] [Related]
16. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
Zanaboni F; Grijuela B; Giudici S; Cormio G; Babilonti L; Ghezzi F; Giorda G; Scambia G; Franchi M; Lorusso M; Ditto A; Lorusso D; Raspagliesi F
Eur J Cancer; 2013 Mar; 49(5):1065-72. PubMed ID: 23151423
[TBL] [Abstract][Full Text] [Related]
17. The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients.
Chen Y; Xu H; Li Y; Wang D; Li J; Yuan J; Liang Z
Ann Surg Oncol; 2008 Oct; 15(10):2847-55. PubMed ID: 18649105
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
19. When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer.
Papadia A; Bellati F; Bogani G; Ditto A; Martinelli F; Lorusso D; Donfrancesco C; Gasparri ML; Raspagliesi F
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S944-51. PubMed ID: 26268452
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
